Immunovant, Inc. (NASDAQ:IMVT) reported fiscal third-quarter results on Friday that showed a smaller loss than analysts had forecast, lifting investor sentiment toward the clinical-stage immunology company.
Shares jumped 7.40% in pre-market trading following the announcement.
For the quarter ended December 31, 2025, Immunovant posted a loss of -$0.61 per share, beating consensus expectations of -$0.72 by $0.11. The net loss totaled $110.6 million, slightly narrower than the $111.1 million loss recorded in the same quarter last year. Research and development spending increased year over year to $98.9 million from $94.5 million, reflecting continued investment in the pipeline, while general and administrative expenses declined to $15.4 million from $19.8 million.
The company ended the quarter with a strong liquidity position, reporting $994.5 million in cash as of December 31, 2025. This was supported by a financing round completed in December that included participation from key institutional investors and Roivant.
Looking ahead, Immunovant expects topline data in the second half of 2026 from its IMVT-1402 study in rheumatoid arthritis as well as from a proof-of-concept trial in cutaneous lupus erythematosus. The company also plans to report results from Phase 3 trials of batoclimab in thyroid eye disease during the first half of 2026, with additional data from potentially registrational studies of IMVT-1402 in Graves’ disease and myasthenia gravis anticipated in 2027.